Depatuxizumab alfa, formerly referred to as ABT-806, represents a unique humanized immunoglobulin targeting the vitronectin associating domain. This therapeutic agent aims to disrupt the formation of the complement membrane attack complex, thus preventing tumor cell spread. Clinical studies have … Read More

Vibostolimab | a | the | this novel | new | emerging antibody | therapeutic | agent represents a | an significant | important | critical advance | step | development in immunotherapy | cancer treatment | therapy. Targeting | focusing | blocking TIGIT, a | an inhibitory | negative | suppressive re… Read More